Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Eli Lilly & Co., consolidated balance sheet: assets (quarterly data)

US$ in thousands

	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash and cash equivalents	2,818,600)	2,380,800)	2,694,500)	3,545,900)	2,067,000)	2,617,400)	2,622,900)	2,459,200)	3,818,500)	3,788,200)	3,220,000)	3,002,400)	3,657,100)	3,595,300)	2,365,100)	1,699,000)	2,337,500)	1,563,800)	2,290,200)	2,036,400)
Short-term investments	109,100)	113,100)	134,600)	123,400)	144,800)	124,700)	113,800)	109,100)	90,100)	37,100)	51,200)	49,000)	24,200)	35,000)	22,800)	78,400)	101,000)	89,200)	77,700)	100,700)
Accounts receivable, net of allowances	9,090,500)	8,167,100)	7,516,100)	7,526,200)	6,896,000)	6,715,300)	6,364,500)	6,322,500)	6,672,800)	5,914,300)	5,829,400)	5,592,800)	5,875,300)	4,886,700)	4,828,900)	5,106,100)	4,547,300)	4,441,700)	4,612,500)	4,200,500)
Other receivables	2,245,700)	2,196,700)	1,655,300)	1,495,900)	1,662,900)	1,609,500)	1,307,900)	1,483,200)	1,454,400)	1,110,700)	1,073,400)	1,065,800)	1,053,700)	958,100)	946,700)	1,246,400)	994,200)	1,096,200)	977,500)	977,500)
Inventories	5,772,800)	4,901,400)	4,798,700)	4,544,800)	4,309,700)	3,831,100)	3,899,400)	3,893,000)	3,886,000)	3,907,400)	3,824,900)	3,660,800)	3,980,300)	3,555,400)	3,313,900)	3,102,400)	3,190,700)	3,101,300)	3,181,100)	3,055,200)
Prepaid expenses and other current assets	5,690,300)	5,247,900)	4,532,400)	3,575,200)	2,954,100)	2,741,900)	2,806,700)	2,697,700)	2,530,600)	3,050,600)	3,296,600)	3,233,700)	2,871,500)	3,209,400)	3,104,500)	2,761,900)	2,538,900)	2,369,600)	2,315,500)	2,227,200)
Current assets	25,727,000)	23,007,000)	21,331,600)	20,811,400)	18,034,500)	17,639,900)	17,115,200)	16,964,700)	18,452,400)	17,808,300)	17,295,500)	16,604,500)	17,462,100)	16,239,900)	14,581,900)	13,994,200)	13,709,600)	12,661,800)	13,454,500)	12,597,500)
Investments	3,052,200)	2,691,700)	2,745,100)	2,750,400)	2,901,800)	2,574,600)	2,587,200)	2,727,300)	3,212,600)	3,350,500)	3,474,900)	3,232,400)	2,966,800)	2,476,200)	2,406,400)	2,148,700)	1,962,400)	1,825,300)	1,852,700)	2,111,400)
Goodwill	4,939,700)	4,085,200)	4,078,900)	4,073,100)	4,073,000)	3,891,600)	3,891,800)	3,892,000)	3,892,000)	3,884,100)	3,884,200)	3,877,400)	3,766,500)	3,726,400)	3,723,200)	3,779,100)	3,679,400)	3,772,500)	3,820,100)	3,855,900)
Other intangibles, net	6,906,600)	6,781,700)	6,903,500)	7,087,100)	7,206,600)	7,124,100)	7,497,700)	7,482,400)	7,691,900)	7,887,700)	7,985,400)	8,087,800)	7,450,000)	7,588,600)	7,712,500)	7,766,700)	6,618,000)	6,689,300)	6,586,600)	6,641,500)
Deferred tax assets	5,477,300)	4,574,800)	3,805,900)	3,406,700)	2,792,900)	2,384,300)	2,371,900)	2,464,900)	2,489,300)	2,625,600)	2,674,900)	2,649,900)	2,830,400)	2,555,300)	2,481,800)	2,471,600)	2,572,600)	2,412,800)	2,507,400)	2,511,000)
Property and equipment, net of accumulated depreciation	12,913,600)	11,863,200)	11,277,400)	10,546,200)	10,144,000)	9,311,300)	9,128,200)	9,102,700)	8,985,100)	8,920,400)	8,855,500)	8,630,100)	8,681,900)	8,281,100)	7,981,100)	7,897,900)	7,872,900)	7,801,500)	7,847,500)	7,780,000)
Other noncurrent assets	4,989,900)	4,911,900)	4,671,600)	4,488,100)	4,337,000)	4,535,700)	4,471,600)	4,285,300)	4,082,700)	3,710,400)	3,638,600)	3,756,200)	3,475,400)	3,078,500)	3,080,100)	3,044,600)	2,871,200)	2,729,900)	2,597,600)	2,509,500)
Noncurrent assets	38,279,300)	34,908,500)	33,482,400)	32,351,600)	31,455,300)	29,821,600)	29,948,400)	29,954,600)	30,353,600)	30,378,700)	30,513,500)	30,233,800)	29,171,000)	27,706,100)	27,385,100)	27,108,600)	25,576,500)	25,231,300)	25,211,900)	25,409,300)
Total assets	64,006,300)	57,915,500)	54,814,000)	53,163,000)	49,489,800)	47,461,500)	47,063,600)	46,919,300)	48,806,000)	48,187,000)	47,809,000)	46,838,300)	46,633,100)	43,946,000)	41,967,000)	41,102,800)	39,286,100)	37,893,100)	38,666,400)	38,006,800)

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Eli Lilly & Co. current assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Property and equipment, net of accumulated depreciation	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Eli Lilly & Co. property and equipment, net of accumulated depreciation increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Noncurrent assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Eli Lilly & Co. noncurrent assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Eli Lilly & Co. total assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Eli Lilly & Co. cash and cash equivalents decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Short-term investments	Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.	Eli Lilly & Co. short-term investments decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Accounts receivable, net of allowances	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Eli Lilly & Co. accounts receivable, net of allowances increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Eli Lilly & Co. inventories increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Eli Lilly & Co. (NYSE:LLY)

Balance Sheet: AssetsQuarterly Data

Assets: Selected Items

Current Assets: Selected Items

Balance Sheet: Assets
Quarterly Data